Clinical Trials Logo

Clinical Trial Summary

To analyze the effect of pretreatment with dydrogesterone vs combined estradiol valerate and dydrogesterone on embryologic parameters, chemical and clinical pregnancy rates of ICSI in women with PCOS.


Clinical Trial Description

Polycystic ovary syndrome (PCOS) is a very common endocrine disorder affecting 5-7% of women in reproductive age. It is the leading cause of anovulatory infertility in this age group. It is characterized by ovulatory dysfunction, hyperandrogenism and polycystic ovary morphology on ultrasonography. Assisted reproductive techniques (ART) are indicated when infertile women with PCOS are unable to become pregnant through standard ovulation induction methods. Many protocols have been used for ovulation induction in ICSI , GNRH agonist and GNRH antagonist protocols are the most commonly used nowadays. GNRH antagonist protocol use has been increased due to its high safety profile and progressive physician experience in controlled ovarian stimulation . Steroid pretreatment is steroid administration in the cycle preceding the ICSI cycle. Due to oligo-menorrhea & unpredictability of menstruation in PCOS, steroid pretreatment is used to schedule the start of an ICSI cycle in women with PCOS. Also, it is expected to synchronize (homogenize) the follicular cohort, and thus increase both oocyte yield and gamete quality. Moreover, steroid pretreatment may have an impact on cycle outcome. For these reasons, more attention has been paid to the potential interest of steroid pretreatments for scheduling GnRH antagonist cycles. Three main options have been used to achieve cycle programming. First the combined oral contraceptive pill (COCS)seems to be effective for scheduling menstruation but is not associated with increased oocyte yield . Furthermore, a meta-analysis pointed out that COCS pretreatment may be associated with fewer clinical pregnancies.Second, synthetic progestogens are good candidates because of their potent suppressive effect on pituitary gonadotrophin secretion and was associated with higher clinical pregnancy rate than COCS, placebo or no treatment. Finally, luteal administration of natural estrogens was proved to improve the synchronization of early antral follicle growth and to allow retrieval of two additional oocytes. Either waiting for a spontaneous menses or using progestin is a better option than using COCs to induce menses in women with PCOS prior to ovarian stimulation using GnRH antagonist protocol for IVF. PCOS women using COCs had a lower live birth rate after fresh embryo transfer when compared with women using progestin for inducing menses or those with spontaneous menses. This difference, however, was not observed in the group who received an FET. Dydrogesterone (DYD) is one of the synthetic forms of progesterone whose molecular structure and pharmacologic properties are closely related to endogenous progesterone .It is an orally active progestin that is non-thermogenetic, non-sedative and does not inhibit gonadotropin release and ovulation. It has weak antimineralocorticoid effects, negligible androgenic and glucocorticoid activities, and no antiandrogenic properties . Levonorgestrel (LNG) and Norgestrel (NG) are potent progestin exerting some androgenic activity, but no glucocorticoid or antimineralocorticoid properties . Estradiol valerate is an estradiol ester, or a prodrug of estradiol. As such, it is an estrogen, or an agonist of the estrogen receptors. The affinity of estradiol valerate for the estrogen receptor is approximately 50 times lower than that of estradiol . In addition, estradiol valerate is rapidly cleaved into estradiol and is unable to reach target tissues in concentrations of significance, if at all .As such, estradiol valerate is essentially inactive in terms of estrogenic effect itself, acting solely as a prodrug to estradiol . Aside from dose adjustment to account for the difference in molecular weight, oral estradiol valerate is considered to be equivalent to oral estradiol. Because estradiol valerate is a prodrug of estradiol, it is considered to be a natural and bioidentical form of estrogen. The current study aims to analyze the effect of pretreatment with dydrogestrone vs combined estradiol valerate and dydrogestrone on embryologic parameters, chemical and clinical pregnancy rates of ICSI for PCOS patients. The current study, being prospective and randomized, will differ from most of the previously conducted studies using steroid pretreatment in ICSI for PCOS patients. It also differs in comparing the pretreatment with dydrogesrone which is similar to natural progesterone with estradiol valerate which is similar to natural estradiol, together with Dydrogestrone. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05300841
Study type Interventional
Source Sohag University
Contact Ahmed Salah
Phone 0201050199550
Email ahmedsalahali37@yahoo.com
Status Not yet recruiting
Phase Early Phase 1
Start date May 1, 2022
Completion date May 1, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT06101147 - Effect of Vitamin D Supplementation on Testosterone Level in Women With Polycystic Ovary Syndrome Phase 2
Completed NCT02037672 - PDE-4 Inhibitor Roflumilast and Polycystic Ovary Syndrome Phase 4
Completed NCT01833949 - Unilateral Laparoscopic Diathermy Adjusted to Ovarian Volume N/A
Completed NCT03608813 - Myo-inositol, D-chiro-inositol and Glucomannan in PCOS
Not yet recruiting NCT05298657 - The Angiotensin-Melatonin Axis in Poor and Hyper Responders for IVF Treatment
Completed NCT05951309 - Myoinositol Treatment and Asprosin Levels in PCOS N/A
Enrolling by invitation NCT04485403 - The Effect of Ibuprofen on Women With PCOS. Phase 2
Not yet recruiting NCT03978013 - Pomegranate Juice Effect on Oxidative Stress in Infertile Women During IVF Treatment N/A
Recruiting NCT03767569 - Myo-inositol as Pretreatment in Hyperandrogenic PCOS Patients Phase 3
Completed NCT05843955 - Non-alcoholic Fatty Liver Disease in Women With Polycystic Ovary Syndrome
Recruiting NCT05971849 - Dampening the Reproductive Axis With Continuous Kisspeptin Phase 1
Recruiting NCT04597099 - Androgen Blockade and Progesterone Augmentation of Gonadotropin Secretion Early Phase 1
Active, not recruiting NCT05206448 - Randomized Controlled Trial of Combined Letrozole and Clomid (CLC II) Versus Letrozole Alone for Women With Anovulation Phase 4
Recruiting NCT02358421 - Prediction of High Ovarian Response After Assisted Reproductive Techniques N/A
Completed NCT04113889 - Effects of Triple Drug Cocktail Therapy on Metabolic, Endocrine Alterations and Perceived Stress in Patients With Poly Cystic Ovary Syndrome Phase 2
Completed NCT04562883 - Single vs. Group CAPA-IVM Culture of Cumulus-oocyte Complexes N/A
Recruiting NCT03264638 - A Clinical and Biological Research of Combined Chinese and Western Medicine in the Treatment of PCOS Phase 2
Completed NCT00594217 - Determining How Quickly Progesterone Slows LH Pulse Frequency Phase 1
Recruiting NCT02024984 - Luteal Phase Versus Follicular Phase Administration of Clomiphene Citrate in PCOS, A Randomized Controlled Trial Phase 1
Completed NCT01709942 - Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS) Phase 3